JP2023523568A5 - - Google Patents

Info

Publication number
JP2023523568A5
JP2023523568A5 JP2022562528A JP2022562528A JP2023523568A5 JP 2023523568 A5 JP2023523568 A5 JP 2023523568A5 JP 2022562528 A JP2022562528 A JP 2022562528A JP 2022562528 A JP2022562528 A JP 2022562528A JP 2023523568 A5 JP2023523568 A5 JP 2023523568A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
subject
level
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523568A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/026816 external-priority patent/WO2021211418A1/en
Publication of JP2023523568A publication Critical patent/JP2023523568A/ja
Publication of JP2023523568A5 publication Critical patent/JP2023523568A5/ja
Pending legal-status Critical Current

Links

JP2022562528A 2020-04-13 2021-04-12 ActRIIBリガンドトラップ及びフェドラチニブを使用して貧血を治療するための方法 Pending JP2023523568A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009400P 2020-04-13 2020-04-13
US63/009,400 2020-04-13
PCT/US2021/026816 WO2021211418A1 (en) 2020-04-13 2021-04-12 Methods for treating anemia using an actriib ligand trap and fedratinib

Publications (2)

Publication Number Publication Date
JP2023523568A JP2023523568A (ja) 2023-06-06
JP2023523568A5 true JP2023523568A5 (cg-RX-API-DMAC7.html) 2024-04-05

Family

ID=78085002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562528A Pending JP2023523568A (ja) 2020-04-13 2021-04-12 ActRIIBリガンドトラップ及びフェドラチニブを使用して貧血を治療するための方法

Country Status (10)

Country Link
US (1) US20230181690A1 (cg-RX-API-DMAC7.html)
EP (1) EP4135736A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023523568A (cg-RX-API-DMAC7.html)
KR (1) KR20230003502A (cg-RX-API-DMAC7.html)
CN (1) CN115427056A (cg-RX-API-DMAC7.html)
AU (1) AU2021256419A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020628A2 (cg-RX-API-DMAC7.html)
IL (1) IL297258A (cg-RX-API-DMAC7.html)
MX (1) MX2022012610A (cg-RX-API-DMAC7.html)
WO (1) WO2021211418A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP3227675B1 (en) * 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
CA2983440C (en) * 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
TWI814187B (zh) * 2015-05-13 2023-09-01 美商西建公司 使用ACTRII配位體捕捉以治療β-地中海型貧血
LT3490582T (lt) * 2016-07-27 2024-07-25 Acceleron Pharma Inc. Kompozicijos, skirtos naudoti gydant mielofibrozę
US11202818B2 (en) * 2016-09-14 2021-12-21 President And Fellows Of Harvard College Methods and compositions for modulating erythropoiesis
JOP20190085A1 (ar) * 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018231905A1 (en) * 2017-06-14 2018-12-20 Celgene Corporation Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
MX2021001985A (es) * 2018-08-21 2021-04-28 Sierra Oncology Inc Metodos agnosticos de conteo de plaquetas para tratar la mielofibrosis.
MA53745A (fr) * 2018-09-25 2021-08-04 Impact Biomedicines Inc Procédés de traitement de troubles myéloprolifératifs

Similar Documents

Publication Publication Date Title
JP7342167B2 (ja) 腫瘍を治療するための抗b7-h1抗体
AU2005240082B2 (en) Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients
JP2020524139A5 (cg-RX-API-DMAC7.html)
TWI877239B (zh) 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
JP2016505240A5 (cg-RX-API-DMAC7.html)
CN109661241A (zh) 使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法
JP2019206562A (ja) 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
TW201712035A (zh) 基於過敏反應素-1拮抗劑之癌免疫增強劑
JP2023526590A5 (cg-RX-API-DMAC7.html)
JPH10510553A (ja) 多外傷後の多発性臓器不全の防止のための及び体外血液循環後の急性臓器損傷の防止のための抗−セレクチン抗体
EP4736884A1 (en) Treatment combination, and use thereof and treatment method
CN111533782A (zh) 一种靶向免疫检查点lag-3的活性多肽及其应用
US20240368271A1 (en) Targeting GPR65 for the Treatment of Cancer in Overweight and Obese Individuals
WO2018209017A1 (en) Cancer treatment with a cxcl12 signaling inhibitor and an immune checkpoint inhibitor
CN113117072A (zh) 喹啉衍生物与pd-1单抗的药物组合
US20240150469A1 (en) Anti-b7-h1 antibodies for treating tumors
WO2024037594A1 (en) Combination treatment with orelabrutinib and tafasitamab
EP3008089A1 (en) Combination of cd37 antibodies with chlorambucil
WO2025067383A1 (zh) 用TACI-Fc融合蛋白治疗抗体介导性排斥反应的方法
CN102614180A (zh) 伊曲康唑在制备治疗多发性骨髓瘤药物中的应用
US11324774B2 (en) Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
RU2802962C2 (ru) Композиции и способы лечения рака печени
CN121693348A (zh) 肿瘤联合治疗及使用方法
HK40102408B (en) Pharmaceutical composition containing anti-lag-3 antibody and application thereof
WO2025052354A1 (en) Syk inhibitors for use in the treatment of immune checkpoint inhibition induced adverse events